An article about engineered oral probiotics that sense high glucose and trigger therapeutic responses; it previews a preclinical study exploring this programmable living‑drug approach.
Key Takeaways
- Upon oral administration of the engineered probiotics carrying the sensor
- Demonstrating that long-term oral administration drives clear improvements in lipid profiles
- 3: GIFT-mediated postprandial glycaemic control in DIO mice and db/db mice